The Phase III SERENA-6 trial is the first global trial to use a circulating tumor DNA-guided approach to detect endocrine ...

Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy ...

Daniel Vitt, CEO, Immunic Therapeutics, discusses how the company is positioning itself to lead in the area of gastrointestinal diseases.

The popular medications may still suffer from local shortages, but FDA is confident that the national supply will remain ...

In this Pharmaceutical Executive video interview, Jen Butler, Chief Commercial Officer for Pleio, talks about where patients are turning for trustworthy health information and some strategies that can ...

The application leverages existing clinical data for Uzedy along with prior FDA findings on the safety of Udezy in patients ...

The funding, led by existing and new investors, is expected to support Eikon’s efforts to integrate advanced computing, ...

Daniel Vitt, CEO, Immunic Therapeutics, discusses how the safety and tolerabilities results from Phase I trials for IMU-856 influences further studies for gastrointestinal diseases moving forward.

Take degenerative disc disease, for example. When you take a fibroblast cell and you put it into the nucleus of the disc, you ...

In this Pharmaceutical Executive video interview, Jen Butler, Chief Commercial Officer of Pleio, discusses the significant threat of misinformation to public health and how emotional appeal plays a ...

Daniel Vitt, CEO, Immunic Therapeutics, discusses how IMU-856 could support the challenges of gluten-free diets and cross-contamination risks for celiac disease.

Surgifort is the first FDA-approved human milk-based fortifier specifically designed for term infants recovering from ...